

When you take a multi-targeted approach* across patient types

Consider Acthar® Gel in the treatment of rheumatoid arthritis (RA)

Patient type:

Recurring disease activity; tough-to-treat disease; high disease activity.



Not an actual patient.

Clinical case study

Diagnosis: Rheumatoid arthritis

Woman, aged 71 years, with pain, swelling, and joint stiffness for 4 years.

Case study provided by:

Ara Dikranian, MD

Cabrillo Center for Rheumatic Disease
El Cajon, California

This case study is provided for general medical education purposes only and is not a substitute for independent clinical medical judgment. The intent of this case study is to present the experience of an individual patient, which may not represent outcomes in the overall patient population. Response to treatment may vary from patient to patient.

*Acthar Gel is indicated for certain immune-mediated and idiopathic conditions across a range of therapeutic areas and may be appropriate for multiple patient types.

INDICATION

Acthar® Gel is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Acthar is contraindicated:

- For intravenous administration
- In infants under 2 years of age who have suspected congenital infections
- With concomitant administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of Acthar
- In patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin

Please see additional Important Safety Information throughout and full [Prescribing Information](#).

Acthar® GEL
(repository corticotropin injection) 80 U/mL

History and examination were consistent with recurring disease activity, tough-to-treat disease, and high disease activity

Clinical examination¹

- 4-year history of high disease activity, including acute pain, swelling, and stiffness in all joints
- Exhaustion left her unable to complete usual tasks
- Symptoms affected her day-to-day functioning; could not kneel or grasp small objects as usual
- Lab values:
 - Anti-CCP >200
 - Rheumatoid factors IgM, IgA, IgG=highly positive
- Imaging erosions:
 - MCP joints 2, 3, 4 bilateral
 - Carpal erosions
 - Mild carpal ankylosis bilaterally
- Patient was diagnosed with seropositive rheumatoid arthritis

Treatment history¹

Prescriber	Primary care physician	Previous rheumatologists	Presenting physician
Treatment	<ul style="list-style-type: none"> • Various NSAIDs • Prednisone 20–40 mg daily • Hydrocodone 	<ul style="list-style-type: none"> • DMARDs <ul style="list-style-type: none"> - Methotrexate, sulfasalazine, hydroxychloroquine • Various combination medications containing glucocorticoids 	<ul style="list-style-type: none"> • Biologics <ul style="list-style-type: none"> - Abatacept, rituximab, sarilumab, tocilizumab • Anti-TNF biologics <ul style="list-style-type: none"> - Adalimumab, certolizumab pegol, etanercept, infliximab • JAK inhibitors <ul style="list-style-type: none"> - Baricitinib, tofacitinib, upadacitinib
Outcome	Patient continued having daily pain, swelling and stiffness of various joints, especially shoulders, knees, ankles, feet, hands, and wrists		Each treatment resulted in non-response, inadequate response, or secondary loss of response

SELECT IMPORTANT SAFETY INFORMATION


Warnings and Precautions

- The adverse effects of Acthar are related primarily to its steroidogenic effects
- Acthar may increase susceptibility to new infection or reactivation of latent infections
- Suppression of the hypothalamic-pituitary-adrenal (HPA) axis may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA axis suppression after stopping treatment
- Cushing's syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
- Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Monitor blood pressure and sodium and potassium levels

Patient required an alternative treatment

Decision to treat with Acthar® Gel¹

- Chronic refractory RA required constant steroids, usually 5 mg of prednisone
- Needed frequent prednisone bursts of up to 10 mg, leading to tolerability issues
- Initiated 80 units of Acthar Gel subcutaneously twice weekly



Results after Acthar Gel therapy¹

- 12 weeks after initiation, CDAI improved from 24 to 16
- Off of prednisone 50% of the time; reduced need for dosage >5 mg
- Added anakinra to treatment regimen, resulting in lowered test scores:
 - Best CDAI=4
 - Best RAPID3=7
- During tapers or breaks from Acthar Gel, symptoms worsened
- Decided on maintenance dose of 20–40 units of Acthar Gel twice weekly
- In the past 2 years, symptoms of joint disease have improved
- No adverse events were reported

Anti-CCP=anticyclic-citrullinated peptide; CDAI=Clinical Disease Activity Index; DMARD=disease-modifying antirheumatic drug; IgA=immunoglobulin A; IgG=immunoglobulin G; IgM=immunoglobulin M; JAK=Janus kinase; MCP=metacarpophalangeal; NSAID=nonsteroidal anti-inflammatory drug; RAPID3=Routine Assessment of Patient Index Data 3; TNF=tumor necrosis factor.

Clinical outcomes may not be solely attributable to Acthar Gel.

Dosage should be individualized according to the medical condition of each patient. Frequency and dose of the drug should be determined by considering the severity of the disease and the initial response of the patient.

Sudden withdrawal of Acthar Gel after prolonged use may lead to adrenal insufficiency or recurrent symptoms. It may be necessary to taper the dose and increase the injection interval to gradually discontinue the medication.

Commonly reported postmarketing adverse reactions for Acthar include injection site reaction, asthenic conditions (including fatigue, malaise, asthenia, and lethargy), fluid retention (including peripheral swelling), insomnia, headache, and blood glucose increased.

Reference: 1. Data on file: REF-MNK05118. Mallinckrodt ARD LLC.

Please see additional Important Safety Information throughout and full [Prescribing Information](#).

Acthar® GEL
(repository corticotropin injection) 80 U/mL

When you take a multi-targeted approach* across patient types

Consider Acthar® Gel in the treatment of rheumatoid arthritis (RA)

Patient type:

Recurring disease activity; tough-to-treat disease; high disease activity.

*Acthar Gel is indicated for certain immune-mediated and idiopathic conditions across a range of therapeutic areas and may be appropriate for multiple patient types.

IMPORTANT SAFETY INFORMATION

Contraindications

Acthar is contraindicated:

- For intravenous administration
- In infants under 2 years of age who have suspected congenital infections
- With concomitant administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of Acthar
- In patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, or sensitivity to proteins of porcine origin

Warnings and Precautions

- The adverse effects of Acthar are related primarily to its steroidogenic effects
- Acthar may increase susceptibility to new infection or reactivation of latent infections
- Suppression of the hypothalamic-pituitary-adrenal (HPA) axis may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA axis suppression after stopping treatment
- Cushing's syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
- Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Monitor blood pressure and sodium and potassium levels
- Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy
- Acthar can cause gastrointestinal (GI) bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain GI disorders. Monitor for signs of perforation and bleeding

- Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression to psychosis. Existing conditions may be aggravated
- Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis
- Prolonged use of Acthar may produce cataracts, glaucoma, and secondary ocular infections. Monitor for signs and symptoms
- Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Acthar activity
- There may be an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver
- Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients
- Decrease in bone density may occur. Bone density should be monitored in patients on long-term therapy

Adverse Reactions

- Commonly reported postmarketing adverse reactions for Acthar include injection site reaction, asthenic conditions (including fatigue, malaise, asthenia, and lethargy), fluid retention (including peripheral swelling), insomnia, headache, and blood glucose increased
- The most common adverse reactions for the treatment of infantile spasms (IS) are increased risk of infections, convulsions, hypertension, irritability, and pyrexia. Some patients with IS progress to other forms of seizures; IS sometimes masks these seizures, which may become visible once the clinical spasms from IS resolve

Pregnancy

- Acthar may cause fetal harm when administered to a pregnant woman

Please see full [Prescribing Information](#).



Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.
© 2021 Mallinckrodt. US-2101177 11/21

Acthar® GEL
(repository corticotropin injection) 80 U/mL